Lixte Biotechnology

56 articles with Lixte Biotechnology

• Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors

  4/30/2020

  Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) noted that investigators at the National Cancer Institute (NCI) and National Institute of Neurological Disorders and Stroke (NINDS) reported that Lixte’s lead clinical compound, LB-100, enhanced pharmacological immunotherapy of intracranial brain tumors in immune-competent mice including 25% complete regression and immunity to tumor rechallenge (Journal of Neuro-oncology, on-line April 27

• Yun Yen, MD, PhD and Winson (Sze Chun) Ho, MD Join Lixte Biotechnology’s Board of Directors

  8/8/2018

  Lixte Biotechnology Holdings, Inc. announced the appointments of two new members to the Board of Directors of Lixte: Yun Yen, MD, PhD and Winson (Sze Chun) Ho, MD.

• Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported To Be A Potentiator Of Immunotherapy In An Animal Model

  4/18/2017

• Late-Breaking Abstract On LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, In Combination With A PD-1 Inhibitor In An Animal Model To Be Presented At The AACR Annual Meeting

  3/10/2017

• First-In-Human Assessment Of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published In Clinical Cancer Research

  1/5/2017

• Dr. Stephen Forman Joins Lixte Biotechnology's Board Of Directors

  6/7/2016

• Lixte Biotechnology's Lead Compound LB-100 Reported To Rapidly Improve Symptoms In A Rodent Model of Depression

  2/3/2016

• Lixte Biotechnology Completes Private Placement Of Convertible Preferred Stock

  1/25/2016

• Lixte Biotechnology Completes Private Placement Of Convertible Preferred Stock

  3/18/2015

• Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies

  2/25/2015

• Lixte Biotechnology's LB-100 Selected As One Of Informa And Kantar Health's 2014 Top 10 Most Interesting Oncology Projects To Watch

  11/6/2014

• Lixte Biotechnology's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer

  6/18/2014

• Lixte Biotechnology's Lead Compound Lb-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer

  6/18/2014

• Dr. Daniel Von Hoff Joins Lixte Biotechnology's Scientific Advisory Board

  1/7/2014

• Lixte Biotechnology Announces Initiation of a Phase I Trial of Its Lead Anti-Cancer Compound, LB-100

  4/25/2013

• Lixte Biotechnology Holdings Announces New Appointment to Board of Directors

  11/27/2012

• Lixte Biotechnology Announces Increased Funding and FDA Allowance to Conduct A Phase I Trial of Its Lead Anti-Cancer Compound, LB-100

  7/31/2012

• Lixte Biotechnology Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound

  5/1/2012

• Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor

  4/4/2012

• Lixte Biotechnology Announces Issuance of U.S. Patent for Agents for the Treatment of Neurodegenerative Diseases

  1/9/2012